ADVERTISEMENT

Taguig City's active COVID-19 cases breach 1,000 mark anew

Published Jan 26, 2022 09:00 pm

The total number of active coronavirus disease (COVID-19) cases in Taguig has breached the 1,000 mark again amid the transmission of Omicron variant in the National Capital Region (NCR).

Taguig’s City Epidemiology and Disease Surveillance (CEDSU) reported that as of Jan. 25, there were 1,101 active COVID-19 cases in the city, up by 162 cases or 17 percent from 939 tallied on Jan. 24.

Disinfection in Taguig (Bureau of Fire Protection-Taguig)

In the latest update, CEDSU recorded 395 new COVID-19 cases from 388 the previous day, and 233 new recoveries.

Taguig has 57,996 confirmed COVID-19 cases, 56,454 recovered patients, and 441 deaths as of Jan. 25.

According to Dr. Guido David of OCTA Research, based on data from the Department of Health, Taguig added 155 new COVID-19 cases on Jan. 25, ranking seventh among the 17 local government units (LGUs) in the National Capital Region.

In the last seven days, Taguig added 2,111 cases from 55,885 confirmed cases on Jan. 19 to 57,996 on Jan. 25, or an average of 302 new cases per day.

Meanwhile, the Taguig Safe City Task Force issued the updated guidelines on quarantine, isolation and testing in the city.

Based on the DOH’s Memorandum No. 2022-0013, the following guidelines will be implemented:

A. QUARANTINE OF ASYMPTOMATIC CLOSE CONTACTS

1. The quarantine period for fully vaccinated asymptomatic close contacts shall be at least five (5) days from the date of the last exposure;

2. The quarantine period for partially vaccinated or unvaccinated asymptomatic close contacts shall be at least fourteen (14) days from the date of the last exposure;

3. The quarantine period for fully vaccinated healthcare workers who have received their booster shot may be shortened up to zero (0) days upon approval of their respective Hospital Infection Prevention and Control Committees (IPCC); and

4. The quarantine period for partially vaccinated or unvaccinated healthcare workers shall be at least fourteen (14) days from the date of the last exposure.

Quarantine can be discontinued at the end of the set period if the individual has remained asymptomatic during the whole recommended quarantine period regardless if testing has been done and resulted negative.

B. ISOLATION OF INDIVIDUALS WITH SYMPTOMS AND SUSPECT, PROBABLE, AND CONFIRMED CASES

1. All asymptomatic and fully vaccinated confirmed cases shall be isolated for at least seven (7) days from date of testing;

2. All asymptomatic and partially vaccinated or unvaccinated confirmed cases shall be isolated for at least ten (10) days from date of testing;

3. All confirmed cases experiencing mild or moderate symptoms shall be isolated for at least ten (10) days from the onset of signs and symptoms;

4. All confirmed cases experiencing severe and critical symptoms shall be isolated for at least twenty one (21) days from the onset of signs and symptoms;

5. All symptomatic immunocompromised confirmed cases shall be isolated for at least twenty one (21) days from the onset of signs and symptoms, regardless of vaccination status. These shall include patients with:

a. Autoimmune disease

b. HIV

c. Cancer/malignancy

d. Undergoing steroid treatment

e. Transplant patients

f. Patients with poor prognosis or bed-ridden

6. The isolation period for fully vaccinated healthcare workers who have received their booster shot, whether asymptomatic or experiencing mild symptoms, may be shortened up to five (5) days upon approval of their respective Hospital Infection Prevention and Control Committees (IPCC); and,

7. All partially vaccinated or unvaccinated healthcare workers, experiencing moderate, severe or critical symptoms, shall be isolated for at least ten (10) days from the onset of signs and symptoms.

If symptoms develop within or after the prescribed period for asymptomatic or mild cases, regardless of vaccination status, the individual shall complete the required days of isolation depending on the severity of symptoms.

For asymptomatic, mild, moderate, severe and critical cases, isolation can be discontinued without the need for repeat testing, regardless of vaccination status, upon completion of the recommended isolation period, provided that they do not have fever for at least 24 hours without the use of any medications and shall have improvement of respiratory signs and symptoms.

Related Tags

taguig covid-19 Taguig COVID-19 cases quarantine isolation OMICRON VARIANT
ADVERTISEMENT
.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1561_widget.title }}

.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1562_widget.title }}

.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1563_widget.title }}

{{ articles_filter_1564_widget.title }}

.mb-article-details { position: relative; } .mb-article-details .article-body-preview, .mb-article-details .article-body-summary{ font-size: 17px; line-height: 30px; font-family: "Libre Caslon Text", serif; color: #000; } .mb-article-details .article-body-preview iframe , .mb-article-details .article-body-summary iframe{ width: 100%; margin: auto; } .read-more-background { background: linear-gradient(180deg, color(display-p3 1.000 1.000 1.000 / 0) 13.75%, color(display-p3 1.000 1.000 1.000 / 0.8) 30.79%, color(display-p3 1.000 1.000 1.000) 72.5%); position: absolute; height: 200px; width: 100%; bottom: 0; display: flex; justify-content: center; align-items: center; padding: 0; } .read-more-background a{ color: #000; } .read-more-btn { padding: 17px 45px; font-family: Inter; font-weight: 700; font-size: 18px; line-height: 16px; text-align: center; vertical-align: middle; border: 1px solid black; background-color: white; } .hidden { display: none; }
function initializeAllSwipers() { // Get all hidden inputs with cms_article_id document.querySelectorAll('[id^="cms_article_id_"]').forEach(function (input) { const cmsArticleId = input.value; const articleSelector = '#article-' + cmsArticleId + ' .body_images'; const swiperElement = document.querySelector(articleSelector); if (swiperElement && !swiperElement.classList.contains('swiper-initialized')) { new Swiper(articleSelector, { loop: true, pagination: false, navigation: { nextEl: '#article-' + cmsArticleId + ' .swiper-button-next', prevEl: '#article-' + cmsArticleId + ' .swiper-button-prev', }, }); } }); } setTimeout(initializeAllSwipers, 3000); const intersectionObserver = new IntersectionObserver( (entries) => { entries.forEach((entry) => { if (entry.isIntersecting) { const newUrl = entry.target.getAttribute("data-url"); if (newUrl) { history.pushState(null, null, newUrl); let article = entry.target; // Extract metadata const author = article.querySelector('.author-section').textContent.replace('By', '').trim(); const section = article.querySelector('.section-info ').textContent.replace(' ', ' '); const title = article.querySelector('.article-title h1').textContent; // Parse URL for Chartbeat path format const parsedUrl = new URL(newUrl, window.location.origin); const cleanUrl = parsedUrl.host + parsedUrl.pathname; // Update Chartbeat configuration if (typeof window._sf_async_config !== 'undefined') { window._sf_async_config.path = cleanUrl; window._sf_async_config.sections = section; window._sf_async_config.authors = author; } // Track virtual page view with Chartbeat if (typeof pSUPERFLY !== 'undefined' && typeof pSUPERFLY.virtualPage === 'function') { try { pSUPERFLY.virtualPage({ path: cleanUrl, title: title, sections: section, authors: author }); } catch (error) { console.error('ping error', error); } } // Optional: Update document title if (title && title !== document.title) { document.title = title; } } } }); }, { threshold: 0.1 } ); function showArticleBody(button) { const article = button.closest("article"); const summary = article.querySelector(".article-body-summary"); const body = article.querySelector(".article-body-preview"); const readMoreSection = article.querySelector(".read-more-background"); // Hide summary and read-more section summary.style.display = "none"; readMoreSection.style.display = "none"; // Show the full article body body.classList.remove("hidden"); } document.addEventListener("DOMContentLoaded", () => { let loadCount = 0; // Track how many times articles are loaded const offset = [1, 2, 3, 4, 5, 6, 7, 8, 9, 10]; // Offset values const currentUrl = window.location.pathname.substring(1); let isLoading = false; // Prevent multiple calls if (!currentUrl) { console.log("Current URL is invalid."); return; } const sentinel = document.getElementById("load-more-sentinel"); if (!sentinel) { console.log("Sentinel element not found."); return; } function isSentinelVisible() { const rect = sentinel.getBoundingClientRect(); return ( rect.top < window.innerHeight && rect.bottom >= 0 ); } function onScroll() { if (isLoading) return; if (isSentinelVisible()) { if (loadCount >= offset.length) { console.log("Maximum load attempts reached."); window.removeEventListener("scroll", onScroll); return; } isLoading = true; const currentOffset = offset[loadCount]; window.loadMoreItems().then(() => { let article = document.querySelector('#widget_1690 > div:nth-last-of-type(2) article'); intersectionObserver.observe(article) loadCount++; }).catch(error => { console.error("Error loading more items:", error); }).finally(() => { isLoading = false; }); } } window.addEventListener("scroll", onScroll); });

Sign up by email to receive news.